IN BRIEF: Astra pushes to get Imfinzi approved for lung cancer in US

AstraZeneca PLC - Cambridge, England-based pharmaceutical firm - Says it is "committed to working ...

Alliance News 26 July, 2024 | 12:27PM
Email Form Facebook Twitter LinkedIn RSS

AstraZeneca PLC - Cambridge, England-based pharmaceutical firm - Says it is "committed to working closely" with the US Food & Drug Administration to bring an Imfinzi-based treatment to patients with resectable non-small cell lung cancer, following a review of a phase III trial by the Oncologic Drugs Advisory Committee, an advisory body for the FDA. Astra says the Aegean trial of Imfinzi, whose generic name is durvalumab, showed a "statistically significant and clinically meaningful 32% reduction in the risk of recurrence, progression events or death versus chemotherapy alone".

Astra says the discussion with the ODAC noted that "while the contribution by phase of neoadjuvant and adjuvant components of the perioperative regimen could not be clearly assigned based on the trial design, this is an important potential regimen for patients." The company notes that the FDA isn't bound by the advisory body's recommendation.

Imfinzi already is approved in Switzerland and the UK for treating resectable lung cancer, based on the Aegean trial results.

Current stock price: 12,172.00 pence, up 0.9% in London on Friday

12-month change: up 14%

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 12,180.00 GBX 1.00

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures